ReviewCurrent pharmaceutical design2004
New technologies for drug delivery across the blood brain barrier.
Review in Current pharmaceutical design, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 131 citations in OpenAlex.
- Concentration-Dependent Anticancer Effects of Melittin-Functionalized Nanomaterials.Materials (Basel, Switzerland) · 2026Review
- Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies.International journal of molecular sciences · 2025Review
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Review
- Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration.iScience · 2023Review
- Whether Erythropoietin can be a Neuroprotective Agent against Premature Brain Injury: Cellular Mechanisms and Clinical Efficacy.Current neuropharmacology · 2022Review
- Nanotechnology-based drug delivery for the treatment of CNS disorders.Translational neuroscience · 2022Review
- Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand.Biomaterials · 2020Review
- Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- eBrain: a Three Dimensional Simulation Tool to Study Drug Delivery in the Brain.Scientific reports · 2019Article
- Evolution of macromolecular complexity in drug delivery systems.Nature reviews. Chemistry · 2017Article
- The Potential of Stimuli-Responsive Nanogels in Drug and Active Molecule Delivery for Targeted Therapy.Gels (Basel, Switzerland) · 2017Review
- Recent trends on hydrogel based drug delivery systems for infectious diseases.Biomaterials science · 2016Review
- Amphiphilic cationic nanogels as brain-targeted carriers for activated nucleoside reverse transcriptase inhibitors.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2015Article
- Acute oral toxicity and biodistribution study of zinc-aluminium-levodopa nanocomposite.Nanoscale research letters · 2015Article
- Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.Drug delivery and translational research · 2012Article
- Bioconjugated pluronic triblock-copolymer micelle-encapsulated quantum dots for targeted imaging of cancer: in vitro and in vivo studies.Theranostics · 2012Article
- Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil.TheScientificWorldJournal · 2012Article
- Nanoparticulate systems for drug delivery and targeting to the central nervous system.CNS neuroscience & therapeutics · 2011Review
- Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.Molecular pharmaceutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves artificial hydrophobization of peptides and proteins that facilitates the delivery of these peptides and proteins across BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.